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Abstract
Background: Fractalkine/CX3CL1 and its cognate receptor CX3CR1 are abundantly expressed in the CNS.
Fractalkine is an unusual C-X3-C motif chemokine that is important in neuron-microglial communication, a co-
receptor for HIV infection, and can be neuroprotective. To assess the effects of fractalkine on opiate-HIV interactive
neurotoxicity, wild-type murine striatal neurons were co-cultured with mixed glia from the striata of wild-type or
Cx3cr1 knockout mice ± HIV-1 Tat and/or morphine. Time-lapse digital images were continuously recorded at
20 min intervals for up to 72 h using computer-aided microscopy to track the same cells repeatedly.
Results: Co-exposure to Tat and morphine caused synergistic increases in neuron death, dendritic pruning, and
microglial motility as previously reported. Exogenous fractalkine prevented synergistic Tat and morphine-induced
dendritic losses and neuron death even though the inflammatory mediator TNF-a remained significantly elevated.
Antibody blockade of CX3CR1 mimicked the toxic effects of morphine plus Tat, but did not add to their toxicity;
while fractalkine failed to protect wild-type neurons co-cultured with Cx3cr1
-/--null glia against morphine and Tat
toxicity. Exogenous fractalkine also normalized microglial motility, which is elevated by Tat and morphine co-
exposure, presumably limiting microglial surveillance that may lead to toxic effects on neurons. Fractalkine
immunofluorescence was expressed in neurons and to a lesser extent by other cell types, whereas CX3CR1
immunoreactivity or GFP fluorescence in cells cultured from the striatum of Cx3cr1
-/- (Cx3cr1
GFP/GFP) mice were
associated with microglia. Immunoblotting shows that fractalkine levels were unchanged following Tat and/or
morphine exposure and there was no increase in released fractalkine as determined by ELISA. By contrast, CX3CR1
protein levels were markedly downregulated.
Conclusions: The results suggest that deficits in fractalkine-CX3CR1 signaling contribute to the synergistic
neurotoxic effects of opioids and Tat. Importantly, exogenous fractalkine can selectively protect neurons from the
injurious effects of chronic opioid-HIV-1 Tat co-exposure, and this suggests a potential therapeutic course for
neuroAIDS. Although the cellular mechanisms underlying neuroprotection are not certain, findings that exogenous
fractalkine reduces microglial motility and fails to protect neurons co-cultured with Cx3cr1
-/- mixed glia suggest
that fractalkine may act by interfering with toxic microglial-neuron interactions.
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Opioid drugs can increase HIV replication and modify
HIV pathogenesis through direct interactions with opioid
receptor-expressing cells in the immune system [1-5].
We found that opioids can potentiate the neurodegenera-
tive effects of HIV-1 in the central nervous system (CNS)
through direct actions at μ-opioid receptor expressing
neural cells [6-10], which has support from findings in
nonhuman primates [2] and clinical studies [11,12]. The
“opioid-cytokine connection” has been proposed to high-
light the interrelatedness of the opioid and chemokine
systems in HIV disease progression [13,14]. Not only can
opioids potentiate the production of chemokines that are
known mediators of HIV encephalitis, such as CCL5/
RANTES and CCL2/MCP-1 [15-17], but opioid and che-
mokine systems can undergo mutual cross-desensitiza-
tion [18,19], and opioid and chemokine receptors may
interact directly at the molecular level through the
formation of heterodimers [20-22].
Fractalkine (CX3CL1) [23] and its receptor CX3CR1
[24] are widely distributed within the nervous system
[25,26] in rodents and humans. Unlike other chemokines,
fractalkine and its receptor have a unique structural motif
(CX3C) and are the only ligand-receptor pair within the
CX3C subgroup. Accordingly, fractalkine does not cross-
react with other chemokine receptors and CX3CR1 is not
activated promiscuously by other chemokines [23,27,28].
Functionally, fractalkine is highly pleiotropic [23,27],
acting as both an adhesion molecule and chemoattractant
for T cells, NK cells, and macrophages [24,29,30].
CX3CR1 can also serve as an HIV-1 co-receptor with
CD4 [31-33] and is hypothesized to facilitate the spread
of HIV-1 infection [34]. Within the nervous system, frac-
talkine serves a major role as a membrane-tethered neu-
ronal chemokine, while the Cx3cr1 gene is highly
expressed by microglia [26,35]. There are reports sug-
gesting that the receptor is also expressed by neurons
and other glial types [25,26,36]. Importantly, emerging
evidence indicates that when anchored to the neuronal
plasma membrane, fractalkine can modify the actions of
microglia. Depending on context, fractalkine can impart
life-or-death signals through CX3CR1. CX3CR1 engage-
ment can restrict the aggressiveness of activated micro-
glia [37,38], or can protect neurons from exposure to
HIV-1 Tat [39] or gp120 through the activation of Akt/
PKB [36]. Alternatively, Cx3cr1 gene deletion has been
shown to limit microglial-mediated neuron death in
Alzheimer’s disease [40].
Fractalkine levels are increased in HIV-associated neu-
rocognitive disorders (HAND) [41-43] and in pediatric
patients with HIV-1 encephalitis [39]. Increased fractalk-
ine expression has been proposed as a both a mechanism
of compensatory neuroprotection as part of a generalized
response to lentiviral infections in the CNS [39,44] and
as contributing to the neuronal injury without affecting
neuronal death in neuroAIDS [43]. By contrast, other
investigators report reductions in fractalkine and
CX3CR1 levels and signaling in neuroAIDS [45]. More
recently, fractalkine has been proposed as important for
trafficking HIV-infected lymphocytes into the brain
[34,42]. Soluble fractalkine attenuates gp120 toxicity in
hippocampal neuron cultures in the presence or absence
of a glial feeder layer suggesting a direct neuroprotective
role [46]. Fractalkine can also modify neuronal signaling
through b1-integrins [47]. Interestingly, Tat possesses an
Arg-Gly-Asp (RGD) domain [48] and can bind to a5b1
integrin [49], as well as several other integrins including
avb3a n davb5 [49-51], which suggests at least one pos-
sible molecular site where fractalkine and HIV-1 Tat
might interact.
Fractalkine injections into the periaqueductal grey
attenuate the antinociceptive effects of μ, δ,o r opioid
receptor activation, while fractalkine itself has no effect,
suggesting heterologous cross-desensitization between
CX3CR1 and several opioid receptor types [52]. Moreover,
intrathecal administration of CX3CR1 blocking antibodies
potentiates morphine analgesia, which was interpreted to
result from the blockade of fractalkine-induced increases
in IL-1b and inflammatory pain [53]. Activation of canna-
binoid receptors with WIN55,212-2 reduced fractalkine
expression by human astrocytes through actions at p38
MAPK that were attenuated by the type 2 cannabinoid
receptor antagonist SR144528 [54]. By contrast, fractalkine
does not appear to mediate methamphetamine-induced
neurotoxicity [55].
These findings prompted us to ascertain whether dis-
ruptions in fractalkine-CX3CR1 signaling might underlie
the exaggerated CNS pathology seen with opioid abuse-
HIV-1 comorbidity. The data presented herein suggest
that morphine and HIV-1 Tat co-exposure may contri-
bute to neuronal injury by downregulating CX3CR1, and
thus interfering with fractalkine signaling. Importantly,
soluble fractalkine provided exogenously can rescue neu-
rons from the accelerated injury and death caused by
combined morphine and Tat in the presence of wild-type
glia.
Results
The distribution of fractalkine immunofluorescence sug-
gested that the chemokine was primarily expressed by
neurons, although other cell types occasionally displayed
fractalkine immunoreactivity, including subsets of astro-
cytes as previously reported [25,56]. In untreated control
cultures, robust fractalkine immunoreactivity is evident in
MAP2-immunopositive neurons (Figure 1A). In contrast
to fractalkine, the most intense CX3CR1 immunofluores-
cence was punctate and associated with CD11b-immunor-
eactive microglia (1B; arrows). Preabsorbed fractalkine
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shown).
Effect of Tat and morphine on levels of fractalkine and
CX3CR1
To detect fractalkine by immunoblot, we used an anti-
body directed against the N-terminal chemokine domain
(AF472; R&D Systems, Minneapolis, MN). In immuno-
blots of whole-cell lysates, which include neurons, astro-
glia and microglia, fractalkine presented as an
approximately 95-kDa band (Figure 1C). Recombinant,
non-glycosylated fractalkine, which served as a positive-
control, resulted in a 90-kDa band [57]. The relative
abundance of either variant appeared to be unaffected
Figure 1 Characterization and effects of morphine and/or HIV-1 Tat exposure on bound and soluble fractalkine, and CX3CR1 levels in
mixed striatal neuron-glia cultures. Fractalkine immunofluorescence was readily co-localized in MAP2-positive neuron cell bodies and
dendrites (A), while a majority of the CX3CR1 immunoreactive cells were CD11b-positive microglia (B); scale bar = 15 μm. Fractalkine derived
from neuron-glial co-cultures presented a prominent band at approximately 95-kDa (C). This is slightly higher than the non-glycosylated,
recombinant fractalkine (rFKN) control protein detected at 90-kDa; 0.1 μg and 0.025 μg fractalkine (FKN) were loaded onto the left-hand lanes.
The relative abundance of either variant appeared to be unaffected by morphine (Morph) and/or Tat treatment at 24 h (C); n = 3 experiments.
The amount of fractalkine released into the culture medium was unaffected following 2 h of morphine and/or Tat exposure (D); the limit of
fractalkine detection by ELISA was 320 pg/ml (standard curve in D); n = 3 experiments. Unlike fractalkine, treatment with morphine and Tat
together significantly reduced CX3CR1 levels (~47-kDa) at 24 h, but not 6 h or 12 h, compared to vehicle-treated controls (E) (*P < 0.02 vs.
vehicle-treated controls; Kruskal-Wallis ANOVA and nonparametric post hoc tests), while CX3CR1 levels were unaffected by exposure to morphine
or Tat alone (E); fractalkine and CX3CR1 levels were normalized to actin (~43-kDa bands in C,E) in immunoblots; n = 6 experiments.
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The antibody does not recognize the residual approxi-
mately 20 kDa C-terminal tail that anchors fractalkine
to the cell membrane.
To assess whether morphine and/or Tat treatment
affected fractalkine shedding, the amount of released
fractalkine in the conditioned medium of mixed neuron-
glial cultures was analyzed by ELISA at 2 h following
morphine and/or Tat exposure (Figure 1D). The limit of
detection of the fractalkine assay was 320 pg/ml. Soluble
fractalkine was detected in the medium of vehicle-treated
control cultures (2.50 ± 0.15 ng/ml), suggesting that frac-
talkine is constitutively cleaved and released at relatively
high levels. The proportion of neurons in our cultures
were purposely low relative to numbers of glia (1:20
ratio) to mimic neuron:glia ratios in vivo. Both astroglia
and neurons express fractalkine [25,36,41,54,56,58].
Despite reports that a vast majority of fractalkine origi-
nates from neurons (especially when they are co-cultured
with glia [59]), the neurons in our cultures are vastly out-
numbered by astroglia. Thus, while relatively constant
amounts of fractalkine are released irrespective of mor-
phine and/or Tat exposure, it is difficult to know the
neuronal versus astroglial contribution or the extent to
which more subtle, subcellular changes in neuronal
release might be masked. Thus, the results are inconclu-
sive regarding whether changes in fractalkine shedding
by neurons underlie synergistic morphine-Tat neurotoxi-
city (Figure 1C,D), and additional study is warranted.
To explore possible morphine and/or Tat-induced
alterations in fractalkine receptor expression by micro-
glia, CX3CR1 was examined by immunoblotting. In
mixed striatal cultures, CX3CR1 was detected as a major
band at about 47 kDa, which coincides with its expres-
sion pattern in other cell types [29]. Compared to vehi-
cle-treated controls, CX3CR1 levels were diminished,
although not significantly, in either morphine or Tat-
exposed cultures at 24 h (Figure 1E). Treatment with
morphine and Tat together did significantly reduce
CX3CR1 levels by about 40% compared to controls, but
not compared to cultures treated with morphine or Tat
alone. The findings show that, in combination, morphine
and Tat may cumulatively downregulate CX3CR1 levels
(Figure 1E). CX3CR1 expression was largely restricted to
microglia in our striatal cultures. Accordingly, the
marked decline in CX3CR1 levels with morphine and Tat
co-exposure is presumed to represent a preferential
microglial response. It is also noteworthy that reductions
in CX3CR1 levels occurred despite previous findings that
Tat (14.7 ± 1.3%) or morphine plus Tat (13.7 ± 1.7%)
treatment significantly increases the proportion of micro-
glia in mixed-glial cultures from striatum compared to
controls (8.8 ± 0.6%) [60].
Neurotoxicity
Analyzing the response of individual neurons throughout
the experiment eliminates inter-subject variability and
permits subtle treatment effects to be revealed [61,62].
Computer-aided tracking permits large numbers of neu-
rons (and glia) to be followed and consistently assessed
over time, which greatly facilitates and improves the sen-
sitivity of the assay (Figure 2A-E). Although Tat alone
did not cause significant neurotoxicity relative to controls
at individual times tested, there was a significant interac-
tion effect (
§P < 0.03; Tat × time vs. Control × time) indi-
cating a significantly greater decline in the rate of
survival of Tat-treated neurons compared to controls
from 0 h to 48 h (Figure 2D). This suggests that even
greater proportions of neurons are likely to be lost with
more prolonged Tat exposure, as observed previously
[62]. Alternatively, combined exposure to Tat and mor-
phine caused interactive neuron losses (Figure 2C-D),
similar to the accelerated synergistic neuron death
described previously with morphine and Tat co-adminis-
tration [10] (*P < 0.05) (Figure 2D). These interactive
effects have previously been shown to be selective for
Tat, and do not occur with either denatured or mutant
forms of the viral protein [10,61].
Fractalkine rescues neurons from synergistic morphine
and Tat neurotoxicity
Compared to vehicle controls, neuron viability was unaf-
fected by treatment with fractalkine (1 μg/ml) alone (Figure
2D). By contrast, co-exposure to morphine (500 nM) and
Tat (100 nM) significantly enhanced neuron losses during
the 48 h exposure period (Figure 2C,D), while the synergis-
tic neurotoxicity was entirely prevented by addition of exo-
genous fractalkine (1 μg/ml) to the medium (Figure 2B,D).
Incubation with CX3CR1 blocking antibodies alone was
also neurotoxic, at levels indistinguishable from the com-
bined effects of morphine and Tat (Figure 2E). However,
when anti-CX3CR1 antibodies were co-incubated with
morphine and Tat, there was no additional neurotoxicity
(Figure 2E). This suggests that neuron death is enhanced
when protective signaling through CX3CR1 is attenuated,
either by reducing levels of CX3CR1 (as seen after 24 h
with morphine and Tat co-exposure; Figure 1E), or by phy-
sically limiting CX3CL1-CX3CR1 interactions through
immunoblockade (Figure 2E). Combining CX3CR1 block-
ade with morphine and Tat exposure does not increase the
amount of neuron death seen with morphine and Tat co-
administration alone, perhaps indicating that CX3CR1
function is already maximally reduced in morphine plus
Tat exposed cells. While Tat or morphine by themselves
did not significantly reduce CX3CR1 levels, the trend
towards reduced expression (Figure 1E) suggests that this
might occur with more prolonged exposure.
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Page 4 of 17Figure 2 Effects of fractalkine on morphine and/or HIV-1 Tat-induced toxicity was repeatedly tracked in individual striatal neurons (A-
E). A within-subjects design and computer-assisted, time-lapse tracking of individual neurons is used to compare the survival of the same
neuron before and at 20 min intervals throughout treatments (A-E). Thriving neurons are evident in control (A; neurons 1-3) or morphine
(Morph) + Tat-treated cultures co-administered fractalkine (B; neurons 1-4) at 48 h. By contrast, increased neurodegeneration and death was
apparent with morphine plus Tat exposure (C). Neuron death is often preceded by the systematic degeneration of neurites and fragmentation of
the cell body (Tat + morphine treatment; arrowheads, neuron 1), while death per se occurs precipitously; denoted here by fragmentation of the
cell body and some loss of birefringence (arrow, neuron 1; 44 h and 48 h) (C). Some individual microglia that were tracked are encircled in red,
orange, and yellow, respectively (arrowheads indicate prior movement); there was close association of microglia with the dying (1) and surviving
(2) neuron (not all microglia in the fields are encircled) (C). Neuron death has been confirmed using other viability markers (see text). Many
neurons remain viable despite morphine and Tat co-exposure (e.g., neuron 2); some surrounding cells, including astroglia, immature glial
precursors and microglia, can display sporadic movement; scale bars = 20 μm. While Tat alone did not cause significant neurotoxicity relative to
controls by 48 h [61,62]; there was a significant interaction when overall neuron losses were compared in Tat versus non-Tat vehicle-treated
cultures (
§P < 0.03; Tat × time vs. Vehicle-control × time). Compared to controls or exposure to fractalkine alone, combined morphine and Tat
(Morph+Tat) treatment increased neuronal death at 48 h (D) (*P < 0.05 vs. controls). Exogenous fractalkine (1 μg/ml) (red markers and
connecting lines) prevented the accelerated neuronal death caused by combined Morph+Tat (
#P < 0.05 vs. Morph+Tat) (D). By contrast, CX3CR1
immunoblockade (blue markers and connecting lines) by itself caused significant neurotoxicity that was indistinguishable from the combined
effects of Morph+Tat (E) (*P < 0.05 vs. controls). Moreover, when CX3CR1 blockade was combined with Morph+Tat, there were no additive
neuron losses (E). The findings suggest a critical role for fractalkine-CX3CR1 signalling in potentiating the toxic effects of opioids in Tat-exposed
neurons; data are the mean number of surviving neurons (compared to pretreatment numbers) ± SEM from n = 3-6 experiments; wild-type (WT)
neurons and mixed glia; antibodies (Ab); scale bar = 20 μm.
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To explore the selectivity of fractalkine’s neuroprotective
effect and to begin to discern whether fractalkine is acting
via neuronal or glial receptors, Cx3cr1
-/- (Cx3cr1
GFP/GFP)
mice were obtained and mixed glial cultures established
from their striata. Prior to starting in vitro studies,
Cx3cr1
-/- mice were examined histologically. In the stria-
tum, the predominant GFP
+ cell type was microglia, which
were intensely fluorescent (Figure 3A,B). The intensely
fluorescent GFP
+ cells readily co-localized with ionized
calcium binding adaptor molecule 1 (Iba-1) (Figure 3C), as
previously reported for this Cx3cr1
-/- mouse strain [38],
and high levels of GFP fluorescence were retained
by microglia, but not astrocytes, in mixed glial cultures
(Figure 3D) (Table 1).
In cell cultures, Cx3cr1-null microglia differed consid-
erably from their wild type counterparts. The proportion
of microglia:astrocytes was over 3-fold greater than that
consistently seen in wild-type mixed-glial cultures [60],
despite identical culture conditions in the present study.
When wild-type neurons were co-cultured with Cx3cr1
-/-
glia, baseline levels of neuron death (41.0 ± 3.2% surviv-
ing) appeared to be much greater than losses typically
seen in the presence of wild-type glia (Figure 3E, upper
panel; 77.7 ± 2.7% surviving). Fundamental differences in
cellular makeup and behavior of mixed-glia cultures from
Cx3cr1-null compared to wild type cultures, even prior to
the addition of neurons, negated the validity of direct
“side-by-side” comparisons of neuron survival in co-cul-
ture with wild-type versus Cx3cr1-null mixed glia. How-
ever, in our extensive experience with this co-culture
model [60,63,64], neuron survival rates in control cul-
tures are always between 75-90% at 48 h. The greater
apparent neuron losses might be related to the > 300%
increase in microglial numbers observed inCx3cr1
-/- cul-
tures (Table 1). Importantly, the relative neuroprotective
effects of fractalkine (1 μg/ml) against morphine + Tat
neurotoxicity were abolished when wild-type neurons
were co-cultured with Cx3cr1
-/- mixed glia (Figure 3E),
suggesting fractalkine protection was mediated by
CX3CR1-expressing microglia. Although there were no
differences in survival between vehicle + control versus
fractalkine + control neurons, there is some possibility
that fractalkine enhances baseline neuron survival in the
Cx3cr1
-/- glial co-cultures. This is suggested by signifi-
cant differences only at 48 h between Tat + fractalkine
versus control + fractalkine survival (
§P < 0.05), even
though survival does not differ within control ± fractalk-
ine or Tat ± fractalkine treatments. A similar inconsis-
tency is observed only at 48 h with morphine treatments
(
§P < 0.05). The inconsistencies may result from some
residual actions in the wild-type cells since even the most
highly enriched neuron cultures contain some (< 1%) glia.
Effect of fractalkine on microglial motility
Amoeboid migration as seen in leukocytes is an active
process requiring actin polymerization, which is typically
signaled through small GTPases in response to extracel-
lular stimuli [65]. The chemotactic targeting of infected
or injured cells is a critical aspect of microglial function
as immune effectors. Accordingly, we investigated the
effects of fractalkine on microglial movement. The iden-
tity of individual activated microglia was readily dis-
cerned using phase-contrast microscopy by criteria
described in the Methods, and the identity of individual
cells could be interrogated using immunofluorescent-
tagged antibodies against surface antigens such as Iba-1
shown in Figure 4A-B. Movement differed among indivi-
dual microglia (Figures 4A &5A-C), though the average
movement within a population was quite reproducible
and highly sensitive to extracellular signals (Figure 5A-
D). We measured the linear movement of individual
microglia each hour from 0 to 12 h after treatment. Vehi-
cle-treated microglia migrated an average of 17 μm/h
during this time and motilityi nm i c r o g l i at h a tw e r en o t
exposed to Tat and/or morphine was unaffected by exo-
genous fractalkine (Figure 5D). Treatment with morphine
or Tat alone tended to increase microglial movement, but
the effect was not significant over 12 h. By contrast, con-
tinuous exposure to combined morphine and Tat signifi-
cantly increased the movement of microglia to ~30 μm/
h. In this case, fractalkine (1 μg/ml) significantly inhibited
the increase in microglial migration rate, bringing it back
to pretreatment levels (~17 μm/h) (Figure 5D). The fact
that fractalkine did not reduce baseline motility, and did
not reduce motility increases due to Tat+ morphine to
below pretreatment values, suggests that motility is only
partially controlled by fractalkine and that alternative sig-
nals [66,67] maintain baseline rates of movement.
Effects of morphine and/or Tat ± fractalkine on dendrite
length
There was a tendency for morphine or Tat alone to reduce
dendrite length following 72 h exposure (Figure 6A-E), but
the effects were not significant (Figure 6E). By contrast,
morphine and Tat in combination caused significant
reductions in dendritic complexity in MAP2-immunoreac-
tive striatal neurons after 72 h (Figure 6B,E). Importantly,
concurrent exposure to exogenous fractalkine (1 μg/ml)
prevented the dendritic pruning caused by morphine and
Tat co-exposure (Figure 6D,E).
Effects of fractalkine on the production of TNF-a
TNF-a has been shown to play a central role in initiat-
ing inflammatory cascades in Tat exposed astroglia and
microglia [15,68,69]. ELISA was performed at 12 h fol-
lowing morphine and/or Tat exposure to determine
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-/- mice: Fluorescent images and effects of Cx3cr1
-/- glia on fractalkine-mediated neuroprotection. Images
of the striatum (A-C) and of mixed glial cultures (D) from Cx3cr1
-/- mouse striata. Microglia within the striatum of Cx3cr1
-/- (Cx3cr1
GFP/GFP) mice
fluoresce green (A,B) and are Iba-1 immunoreactive (C); Hoechst counterstained nuclei (blue); scale bars = 50 μm (A) and 10 μm (B,C). Robust
GFP expression is maintained when the cells are placed into culture (D). As can be appreciated from the Hoechst stain, the CX3CR1-expressing
population is significant although the majority of the cells in the culture lack CX3CR1. The loss of CX3CR1 on glia has a dramatic effect on the
ability of fractalkine to protect morphine and Tat-treated striatal neurons (E). Neurons from the striata of wild-type mice were plated onto mixed
glia prepared from Cx3cr1
-/- mouse striata and followed over 48 h using our standard paradigm. In general, wild-type neurons co-cultured with
Cx3cr1
-/- glia appeared to be less viable than with wild-type glia (upper panel; compare gray and black dotted lines); however, these groups
were not compared statistically since the experiments were not run concurrently. The neuroprotective effects of fractalkine (CX3CL1; 1 μg/ml) are
abolished when wild-type neurons are co-cultured with Cx3cr1
-/- mixed glia. Under these conditions, fractalkine no longer protects neurons from
combined morphine and Tat exposure (E, lower panel; *P < 0.05 vs. vehicle- or fractalkine-treated controls). There were no differences in survival
between controls ± fractalkine. Addition of fractalkine did not change the toxicity of morphine, Tat, or morphine + Tat treatments. There is,
however, some possibility that fractalkine enhances baseline neuron survival in the Cx3cr1
-/- glial co-cultures. This was indicated by significant
differences only at 48 h between Tat + fractalkine versus control + fractalkine survival (
§P < 0.05), even though survival did not differ when
comparing vehicle + control vs. fractalkine + control or vehicle + Tat vs. fractalkine + Tat treatments. A similar inconsistency was observed only
at 48 h with morphine treatments (
§P < 0.05).
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Page 7 of 17Figure 4 Computer-assisted, time-lapse tracking of individual microglial cells (A-B). Individual microglia were tracked using phase-contrast
optics (encircled/partially encircled and color-coded), their vectorial movement indicated by the direction and length of arrows/arrowheads (A),
and their identity consistently confirmed by the specific microglial marker Iba-1 (B); scale bar = 20 μm.
Table 1 Effects of morphine and/or HIV-1 Tat exposure ± fractalkine on the percentage of microglia in mixed-glia
cultures from striata of Cx3cr1
-/- (Cx3cr1
GFP/GFP) mice (
‡).
Control Morphine Tat Morphine + Tat
Microglia (%)
(Cx3cr1
-/- mixed glia)
31.0 ± 6.7
§ 26.7 ± 2. 5 26.7 ± 5.1 34.9 ± 1.6
Microglia (%)
(Cx3cr1
-/- mixed glia + fractalkine)
25.8 ± 2.3 25.8 ± 6.7 25.5 ± 4.0 30.9 ± 0.7
‡ No significant effects of morphine and/or HIV-1 Tat ± fractalkine (1 μg/ml) exposure on the proportion of GFP
+ microglia were noted; effects were compared
using 2-way ANOVA.
§ The proportion of microglia in mixed glial cultures from Cx3cr1
-/- mice was much greater than percentages seen in equivalent striatal cultures from wild-type
mice (e.g., 8.8 ± 0.6% Iba-1
+ microglia in control cultures) determined as part of another study [60].
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reducing TNF-a levels in our cultures. As shown before
for striatal astroglia [17,70], Tat ± morphine significantly
increased TNF-a production by these mixed neuronal-
glial cultures (Figure 7); TNF-a production was unaf-
fected by fractalkine or immunoblockade of CX3CR1,
although there was a trend toward increased TNF-a
release in control and morphine-treated cultures with
CX3CR1 blockade (Figure 7). Thus, fractalkine-mediated
protection occurs despite a sustained TNF-a-induced
inflammatory signal.
Discussion
Our results indicate that exogenous fractalkine completely
blocks the synergistic neurotoxicity caused by combined
morphine and Tat exposure. This appears to be mediated
by CX3CR1 expressed by microglia, since fractalkine
neuroprotection is abolished when wild-type neurons are
co-cultured with Cx3cr1-null mixed glia and because
CX3CR1 is almost exclusively expressed by microglia in
these cultures. Moreover, the neuroprotection is accompa-
nied by a marked reduction in microglial motility that was
otherwise significantly increased by morphine and Tat co-
exposure. Although exogenous fractalkine is able to (i) res-
cue opiate and HIV-1 Tat treated neurons and (ii) limit
microglial motility, the present study does not fully discern
the cellular sites or mechanisms of fractalkine’s protective
action. Thus, while the neuroprotective effects of fractalk-
ine are presumed to be due to direct actions on striatal
microglia in the present study, we cannot completely rule
out the possibility that fractalkine can act via alternative
cell types in other brain regions [36,71].
Because the neurotoxic effects of HIV Tat and opiates
were negated by exogenous fractalkine, we questioned
Figure 5 Effects of fractalkine on morphine and/or Tat-induced alterations in microglial motility (A-D) and nitrosative stress (E-F).
Morphine and Tat together (Morph+Tat) increased microglial movement in time-lapse images (representative cells circled in red) (A,B), while
concurrent fractalkine exposure negated the effects of Morph+Tat (representative cells encircled in red) (B,C). When the vectorial trajectories of
individual microglial movement are plotted each hour for 6 h, (i) the sporadic movements of individual cells and (ii) the ability of fractalkine to
attenuate the overall motility are appreciated (B). Measurements confirmed that combined Morph+Tat increased microglia motility compared to
vehicle, morphine, or Tat exposure alone (*P < 0.05). Addition of exogenous fractalkine (1 μg/ml) completely reversed the effect of Morph+Tat
(D) (
#P < 0.05 vs. Morph+Tat alone), returning motility to baseline levels. The average movement of ~100 microglia in each treatment group was
determined by measuring the distance from nuclear position at 0 h vs. 12 h per treatment in each experiment; values are the mean movement
(μm/h) ± SEM from n = 4 experiments. Representative microglia that were tracked are encircled in red; the occasional macrophage/microglial
interlopers that appeared and/or disappeared within the observation field and could not be tracked are circled in yellow; scale bar = 20 μm.
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Page 9 of 17Figure 6 Effects of fractalkine or immunoneutralizing anti-CX3CR1 antibodies on morphine and/or Tat-induced degeneration of MAP2-
immunoreactive dendrites of striatal neurons at 72 h (A-E). Compared to vehicle controls (Con) (A), morphine and Tat (Morph+Tat) (B)
caused significant reductions in dendritic length (*P < 0.05 vs. vehicle controls) (E). Fractalkine prevented Morph+Tat-induced dendritic pruning
(
#P < 0.05 vs. Morph+Tat) (D,E), but by itself had no effect (C,E). Data in E are mean dendrite length (μm) ± SEM from n = 4 experiments; scale
bar = 20 μm.
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Page 10 of 17whether fractalkine-CX3CR1 signaling might be dis-
rupted in neurons and/or glia exposed to opiates and Tat
and began to address this question in a preliminary fash-
ion. A disruption in fractalkine-CX3CR1 signaling by opi-
ate-HIV protein exposure would parallel evidence from a
variety of other CNS disorders where fractalkine-
CX3CR1 interfacing appears to be altered, including Par-
kinson’sa n dA l z h e i m e r ’s diseases, as well as in HIV
dementia [40,44,72]. Close associations between fractalk-
ine-expressing neurons and CX3CR1-positive microglia
have been described in the CNS of pediatric patients with
HIV-1 encephalitis [39], but expression levels of either
the fractalkine ligand or receptor were not ascertained.
More recently, CX3CR1-directed pruning of aberrant
synapses was found to be necessary for normal CNS
maturation [73]. Cx3cr1-null mice retained large num-
bers of immature synapses displaying deficits in neuronal
function and behavior [73]. Assuming restricted fractalk-
ine-CX3CR1 interfacing, an attenuated signal might origi-
nate from a decline in fractalkine, its receptor or both.
Fractalkine has multiple neuroprotective, cell-adhe-
sion, and chemotactic functions through actions as both
a bound and a diffusible factor [37,38]. This complexity
adds to the challenge of understanding fractalkine-
CX3CR1 actions. Membrane-bound fractalkine can func-
tion as an adhesion molecule for cells that express
CX3CR1, while proteolytically released fractalkine func-
tions as a more typical soluble chemokine [30]. Fractalk-
ine is reportedly cleaved by ADAM (a disintegrin and
metalloproteinase) 10 and perhaps ADAM17 (TNF-a
converting enzyme or TACE) [57,74-76]. Cleavage
results in soluble 60-85-kDa fractalkine (depending on
residual glycosylation) and a ~20-kDa transmembrane
C-terminal fragment that remains anchored to the cell
membrane [57]. Once shed, fractalkine undergoes tis-
sue-specific processing, which may contribute to loca-
lized immune responses [77,78]. Soluble fractalkine
limits microglial neurotoxicity [30,36,38], as seen in the
present study, and sustained fractalkine release may be
necessary for continued protection from microglial sur-
veillance [59].
In control cultures, the presence of secreted fractalkine
in the medium suggests that bound fractalkine is constitu-
tively cleaved and tonically released by ADAM10 [74].
ADAM10 is inducible and is acutely sensitive to increases
in [Ca
+2]i caused by excitotoxic levels of glutamate [76].
Despite the potential for dynamic changes in fractalkine
release, the concept that morphine ± HIV-1 Tat exposure
neurotoxicity might be mediated by altered fractalkine
production or shedding is not supported by our findings.
The relative abundance of bound (immunoblots) and
released, soluble fractalkine (ELISA) was unaffected by
morphine or Tat treatments. Nevertheless, additional stu-
dies are needed to address this question systematically.
Although neurons reportedly shed greater amounts of
fractalkine than astroglia [59], because astroglia outnum-
ber neurons in our cultures by ~20-fold, the relative con-
tribution of each to the fractalkine pool is uncertain and a
p o t e n t i a l l yu n i q u er e s p o n s eb yn e u r o n sm a yb e
overshadowed.
There is less agreement regarding how CX3CR1 levels
affect neuron survival or function. CX3CR1 is most often
reported as a ~50-kDa protein [79], which is in agreement
with the present findings, although cell-type specific
CX3CR1 isoforms of ~40 kDa have been reported [80]
that likely result from alternative splicing and/or differ-
ences in CX3CR1 glycosylation [79]. The cellular distribu-
tion and intensity of CX3CR1 immunoreactivity and GFP
in Cx3cr1-null mice indicated that the receptor was
expressed by microglia at high levels in striatum (Figures
1B & 3A-D). In cultures of mixed glia lacking the Cx3cr1
gene, we found the proportion of microglia:astroglia was
much higher. Moreover, when wild-type neurons were co-
cultured with Cx3cr1-null glia, the background rate of
neuron death was much greater than with wild-type glia–
even under identical culture conditions. This suggests
Figure 7 Effects of fractalkine or immunoneutralizing anti-
CX3CR1 antibodies on morphine and/or Tat-induced TNF-a
production by mixed neuron-glial cultures at 12 h. Tat ±
morphine (Morph) significantly increased TNF-a production by
mixed neuronal-glial cultures from striatum (*P < 0.05 vs. vehicle-
treated controls); Tat ± morphine-induced TNF-a production was
unaffected by fractalkine or CX3CR1 immunoblockade, although
there was a trend toward increased TNF-a release in control and
morphine-treated cultures with CX3CR1 blockade.
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deleted and wild-type microglia. The neuroprotective
effects of fractalkine were lost when morphine and Tat-
co-exposed wild-type neurons were cultured with Cx3r1-
knockout glia. This strongly infers that fractalkine protects
neurons through interactions with microglial CX3CR1,
although inherent differences in the cytotoxicity of
Cx3cr1-deleted microglia may represent a confound.
Unlike fractalkine, CX3CR1 levels showed a classic down-
regulation after 24 h continuous exposure to combined
morphine and Tat. The reduction appeared to be additive
s i n c em o r p h i n ea n dT a tb yt h e m s e l v e sb o t hp r o d u c e d
modest, but not significant, reductions in CX3CR1 levels.
Antibody blockade of CX3CR1 caused toxicity equal to
Tat and morphine co-exposure, while Cx3cr1 gene dele-
tion from glia appeared to increase baseline levels of neu-
ron death even in control cultures (see Figure 3E).
Microglial chemotaxis, activation, and overactivation are
regulated by hierarchical signals that are critically impor-
tant in the inactivation/removal of pathogens [81].
Unchecked, microglial overactivation may cause bystander
cytotoxicity [81-83]; yet, microglial activation appears
reversible [81], suggesting an opportunity to allay the dele-
terious consequences of overactivation. HIV-1 or opioid
exposure can trigger key events underlying microglial (and
astroglial) activation including increases in oxyradicals
[84], glutamate secretion [85], and the production of
proinflammatory cytokines and chemokines [15-17,86];
while many of these deleterious signals can be attenuated
by fractalkine/CX3CR1 activation [30,38,44,87,88]. In fact,
increases in fractalkine may be a protective response in
CNS injury and some diseases [89,90]. Our results suggest
that CX3CR1 signaling can short-circuit key aspects of
microglial overactivation caused by morphine and Tat,
thereby enhancing neuron survival and function.
The above findings suggest that CX3CR1 signaling is
fundamentally important for microglial function. In fact, it
has been suggested that deleting the Cx3cr1 gene dysregu-
lates so many aspects of microglial function (including
functions regulating both protective and toxic bystander
effects) that it may no longer be possible to correctly inter-
pret the role of fractalkine-CX3CR1 interactions in a parti-
cular situation [30,37,38]. For example, neuron death was
mitigated by Cx3cr1 deletion in models of Alzheimer’s dis-
ease and ischemia [40,91]. By contrast, neurotoxicity was
exacerbated by Cx3cr1 deletion in three other neuroin-
flammatory models [38], while CX3CR1 is essential for
normal synaptic pruning during maturation [73]. Thus,
the consequences of fractalkine-CX3CR1 signaling appear
to be complex, varying depending on the particular dis-
ease, the brain region studied, and context. Clearly, the
present findings suggest that CX3CR1 regulates critical
microglial functions, and reductions in CX3CR1 levels
coincide with basic imbalances in astroglial:microglial
numerical matching and marked reductions in striatal
neuron viability.
Notwithstanding its chemotactic and surveillance func-
tions [28,37], fractalkine is reported to limit cytotoxicity by
reducing microglial activation and killing [30,37,38]. HIV-
1 Tat induces the production of chemokines that increase
microglial chemotaxis including CCL2/MCP-1 [86,92] and
CCL5/RANTES [15,16]. In the present study, although
exogenous fractalkine completely blocked the increase in
microglial motility caused by combined morphine and Tat
exposure, it had no affect on baseline movement. More-
over, fractalkine negated the synergistic morphine and Tat
neurotoxicity despite elevated levels of TNF-a in the cul-
ture medium. Assuming fractalkine may attenuate micro-
glial activation through an alternative mechanism, we
examined 3-nitrotyrosine and nitrite production, which
are reactive nitrogen byproducts that are highly sensitive
to morphine and HIV-1 Tat interactions [60,93]. In preli-
minary studies, we found that morphine + Tat-induced
increases in both nitrosative byproducts were entirely
unaffected by exogenous fractalkine (1 μg / m l )a t2 4ho r
48 h (data not shown). Additional studies are needed to
assess whether fractalkine might affect other key redox
and proinflammatory pathways in microglia before sug-
gesting that fractalkine’s actions are restricted to microglial
motility or surveillance. Since nitrosative stress and TNF-a
production lie upstream of, and instigate, multiple inflam-
matory signaling events, we propose that fractalkine selec-
tively overrides key aspects of microglia activation at
relatively late stages in the inflammatory process to pre-
vent cytotoxic killing. If this assumption is correct the
findings have considerable therapeutic implications for
chronic substance abuse and HIV-1 comorbidity.
Conclusions
Fractalkine-CX3CR1 signaling in striatal neuron-glia co-
cultures appears to be compromised by opioid drug and
HIV-1 co-exposure, and this may contribute to increased
neuronal injury. Levels of CX3CR1 are reduced by mor-
phine and Tat co-exposure, and the addition of exogen-
ous fractalkine completely prevents the interactive
neurotoxicity. Since CX3CR1 is expressed almost exclu-
sively by microglia in the mixed-glial cultures, this sug-
gests that fractalkine protects neurons against morphine
and Tat co-exposure through direct actions on microglia.
In glia from mice lacking the Cx3cr1 gene the proportion
of microglia:astroglia was much higher and background
rates of neuron death were greater than wild-type glia
even under identical culture conditions, suggesting
fundamental differences between the function of Cx3cr1-
null and wild-type microglia. Despite these inherent dif-
ferences, the neuroprotective effects of fractalkine were
lost when morphine and Tat-co-exposed wild-type neu-
rons are cultured with glia lacking the Cx3r1 gene further
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Thus, fractalkine may have considerable therapeutic
potential in limiting inflammation, microglial overactiva-
tion, and neuronal injury with opioid abuse and/or
neuroAIDS.
Methods
Animals
ICR (CD-1) mice were purchased from Charles River
Inc. (Charles River, MA), while Cx3cr1
-/-(Cx3cr1
GFP/GFP)
mice [26] on a C57BL/6J genetic background were
obtained from Jackson Laboratory (Bar Harbor, ME)
and originally engineered by Dr. Dan Littman (Skirball
Institute, New York University School of Medicine, NY,
NY). In all experiments, mice were anesthetized and/or
euthanized in accordance with NIH and local Virginia
Commonwealth University IACUC guidelines, which
minimize the number of mice used and their possible
discomfort.
Mixed-glial cultures
Mixed glial (astroglia and microglia) cultures were pre-
pared from neonatal (P0-P1) wild-type ICR or Cx3cr1
-/-
mouse striata (Charles River) as previously described
[70]. Striata were dissected, minced, and incubated with
10 ml trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in
serum free medium (30 min, 37°C). Tissue was triturated,
resuspended in 10 ml culture medium with 10% fetal
bovine serum, filtered through 135 μm and then 45-μm
pore nylon mesh, prior to plating (~2.5 × 10
5 cells/cm
2)
on poly-D-lysine coated coverslips. After mixed glia from
wild-type or Cx3cr1
-/- mice were cultured approximately
6-8 days in vitro they were used as a bedlayer for co-cul-
turing neurons. Despite functional deletion of Cx3cr1,
the null gene was engineered to continue to express GFP
as a marker [see [26]]. The proportion of Hoechst
+ cells
in the mixed glial cultures that were GFP
+ was deter-
mined following 48 h of continuous vehicle, morphine,
HIV-1 Tat, or morphine plus Tat exposure (Table 1). At
least 300-500 cells were counted per treatment group in
each experiment (N = 1). Experiments were repeated 3
times and data presented as the mean ± the SEM (N = 3).
Neuronal culture or co-culture with mixed glia from wild-
type or Cx3cr1
-/- (Cx3cr1
GFP/GFP) mice
Striatal neurons were prepared from wild-type E15-E16
ICR (CD-1) mouse embryos. Striata were dissected,
minced, and incubated with 10 ml trypsin (2.5 mg/ml) and
DNase (0.015 mg/ml) in Neurobasal medium (Invitrogen,
Carlsbad, CA) with 25 μM glutamate (30 min, 37°C). Tis-
sue was triturated, resuspended in 10 ml medium, and
cells filtered twice through 70 μm pore nylon mesh.
Isolated wild-type neurons were (i) plated alone on poly-
D-lysine coated coverslips or (ii) co-cultured directly on a
bedlayer of mixed glia derived from wild type or Cx3cr1
-/-
mice. Neuron cultures and neuron-glia co-cultures were
similarly maintained in Neurobasal medium supplemented
with B27, 0.5 mM L-glutamine, 0.025 mM glutamate, and
allowed to mature for about 1 wk prior to the start of the
experiments.
Assessment of neuron viability
Time-lapse digital images were recorded at 20 min inter-
vals for 48 h using a microscope (Zeiss Axio Observer Z.1)
and automated, computer-controlled (AxioVision 4.6;
Mark&Find, MosaiX, and Time Lapse software) stage
encoder with environmental control (37°C, 95% humidity,
5% CO2; PeCon Instruments, Houston, TX), to repeatedly
track the same neurons [64]. Repeated measures ANOVA
was used to compare treatment effects on the same neu-
ron at the onset and throughout the experiment (Statistica;
StatSoft, Tulsa, OK). In each experiment, treatments were
distributed across cells pooled from the same pups.
Approximately 50 healthy neurons with well defined den-
dritic and axonal arbors were identified using phase-con-
trast microscopy (40× magnification) within individual
culture wells in each experiment prior to treatment (0 h)
(Figure 2A-C). The effects of opioids and/or HIV-1 Tat ±
fractalkine or CX3CR1 immunoblockade ± mixed glia
from wild-type or Cx3cr1
-/- mice on neuron survival was
determined at 4 h intervals and averaged per culture well/
treatment (n = 1). Neuron injury and death was monitored
in individual cells and defined by rigorous criteria, which
included dendritic pruning, dissolution of the Nissl sub-
stance, transient cytoplasmic swelling and vacuolization,
nuclear damage, and eventual destruction of the cell body
[61,63,64]. In some cases, neuron death was confirmed by
viability markers such as ethidium homodimer, ethidium
monoazide, or trypan blue (not shown); however, these
markers all possess some inherent cytotoxicity with pro-
longed exposure, which precludes their use to monitor
cells continuously. The effect of each treatment on neuron
survival was analyzed statistically at 4 h intervals using
repeated measures ANOVA from n = 5-6 experiments
(200-300 neurons in total per treatment) and reported as
the mean percentage of surviving neurons, relative to pre-
treatment values ± the standard error of the mean (SEM),
but designated as “% of control” for simplicity.
Experimental treatments
Cultures were continuously treated with recombinant
Tat1-86 (100 nM; from HIV-1IIIB strain, ImmunoDiag-
nostics, Woburn, MA), morphine sulfate (500 nM;
S i g m a ,S t .L o u i s ,M O ) ,f u l l - l e n g t hr e c o m b i n a n tm o u s e
fractalkine (1 μg/ml) (R&D Systems, Inc., Minneapolis,
MN; catalog no. 472-FF/CF), and/or anti-CX3CR1 anti-
bodies lacking azide (Torrey Pines Biolabs, East Orange,
NJ).
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Cell cultures were fixed for 15 min in 3% paraformalde-
hyde in phosphate buffer (pH 7.2 at 4°C), permeabilized in
0.1% Triton-X 100, and rinsed 3 × 20 min in PBS, pH 7.2.
Cultures were incubated in diluted primary antiserum on
an orbital shaker (40-60 rpm) overnight at 4°C in PBS, pH
7.2 with 1% crystalline grade BSA (Calbiochem/EMD Che-
micals, Gibbstown, NJ) and 0.1% Triton-X 100. Rabbit
anti-mouse fractalkine (1:100; catalog no. TP233; Torrey
Pines Biolabs) or rabbit anti-rat CX3CR1 (1:100; catalog
TP501; Torrey Pines Biolabs) antigenicity was co-localized
with antibodies to MAP2 a/b (1:200; catalog MAB 378;
Chemicon, Temecula, CA), glial fibrillary acidic protein
(GFAP) to detect astroglia (1:200; Chemicon), or CD11b
(1:100; catalog No. MAB1124; R&D Systems) to identify
microglia. MAP2, GFAP, and CD11b antigenicity were
detected using appropriate secondary antibodies conju-
gated to Alexa 488 (1:500 dilution; Molecular Probes,
Eugene, OR) or Cy3 (1:250 dilution; Jackson ImmunoRe-
search, West Grove, PA). Cells were counterstained with
Hoechst 33342 (1 μg/ml), which labels all cell nuclei blue.
A rabbit polyclonal antibody against Iba-1 (Wako Chemi-
cals USA, Richmond, VA, 1:500) and an anti-rabbit sec-
ondary antibody conjugated to Alexa 594 were also used
to detect microglia and ascertain the extent of Iba-1-GFP
overlap in mixed glial cultures from Cx3cr1
-/- mice. Cul-
tures were rinsed and mounted in Prolong Antifade com-
pound (Molecular Probes). For measurements of dendrite
length, neuron cell bodies and dendrites were labeled
using anti-MAP2a/b antibodies (1:200; Chemicon) and
secondary antibodies conjugated to horseradish peroxidase
and visualized using diaminobenzidine. Preabsorbed frac-
talkine antibody controls consisted of rabbit anti-murine
fractalkine antibody (R&D Systems) IgG preabsorbed with
25 μg/ml of the recombinant fractalkine peptide epitope
used for antibody production for 1 h at 37°C, 5% CO2 and
in high humidity.
Fluorescence microscopy
Fluorescent images were obtained using Zeiss Axio Obser-
ver Z.1 microscopes configured with widefield fluores-
cence and AxioCam MRm digital camera or configured
with a LSM 700 laser scanning confocal head. Multiple
z-stacks were acquired and compressed into a single pro-
jected image to better show the cells in their entirety using
Zen 2010 software (Zeiss).
Immunoblotting
Western blotting for fractalkine and CX3CR1 was per-
formed using routine methods previously reported by us
[62,64]. Goat anti-mouse fractalkine antibodies (directed
against the N-terminal, chemokine domain; catalog no.
AF472; R&D Systems) were used at 1:1,500 dilution and
rabbit anti-rat CX3CR1 antibodies (TP501; Torrey Pines
Biolabs) were used at 1:1,000 dilution. The same non-gly-
cosylated, recombinant fractalkine that was neuroprotec-
tive against morphine and/or Tat co-exposure (R&D
Systems; catalog no. 472-FF/CF) served as a positive con-
trol. Proteins were detected via HRP and enhanced che-
moluminescence detection (Amersham Biosciences,
Fairfield, CT), and quantified using a Kodak 440 Gel Ima-
ger. Protein levels were normalized to b-actin (1:3,000;
Santa Cruz Biotechnology, Santa Cruz, CA).
ELISA
Fractalkine and TNF-a were assessed by ELISA (R&D
Systems) according to the manufacturer’si n s t r u c t i o n s
using a Victor-3 platereader (Perkin Elmer Co., Wal-
tham, MA) as previously described [64,70].
Microglial migration
Individual microglia were tracked and images acquired at
20 min intervals, analyzed at 1 h intervals, and the average
movement determined during the initial 12 h following
experimental treatments. Microglia are readily identified
in videos as motile, amoeboid cells with cytoplasmic gran-
ularity caused by lysosomes and autophagosomes, and filo-
podial/lamellipodial cytoplasmic extensions. Microglial
identification was verified by immunostaining for Iba-1 at
the end of some experiments (Figure 4B). Microglia were
randomly selected from within the phase-contrast images
at 0 h and the point-to-point distance traveled by each
macrophage/microglia was assessed at 1 h intervals, by
measuring the linear distance from the last position of the
cell body. Because most cells tended not to move in a
straight line at a consistent speed, even measurements at
relatively frequent 1 h intervals underestimated the total
distance traveled by many cells during that time. Despite
some irregular movement by individual microglia, the
average distance traveled per unit time by all microglia
within a particular treatment group was quite reproduci-
ble. Approximately 100 microglia were selected in each
treatment group per experiment. Cells that moved out of
the viewing field were excluded from the determination.
Data are presented as the mean migration rate (μm/h) ±
SEM from 4 experiments.
Dendrite length estimates
After the time lapse studies were completed at 72 h, cul-
tures were fixed for 15 min with ice-cold Zamboni’s fixa-
tive, washed in PBS (3 × 5 min), and incubated with anti-
rabbit microtubule associated protein-2 (MAP2) antibo-
dies overnight at 4°C (1:200 dilution; Chemicon). MAP2
immunofluorescence was detected using biotinylated sec-
ondary antibodies conjugated to peroxidase (Jackson
ImmunoResearch, West Grove, PA) and visualized using
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all dendrites within a defined area was estimated by their
intersections with calibrated concentric circles using the
Scholl procedure [94,95], but with slight modifications for
in vitro measurements [61]. The mean dendritic length
per neuron was calculated from approximately 40-60 neu-
rons sampled per treatment group in each experiment;
experiments were repeated at least 3 times and data pre-
sented as the mean dendritic length per neuron ± SEM
per experiment.
Statistical analyses
Statistical analyses were done by repeated measures, one-
way, and two-way analysis of variance (ANOVA) followed
by Duncan’so rB o n f e r r o n i ’s post-hoc testing (StatSoft,
Statistica, Tulsa, OK).
List of Abbreviations
ADAM: a disintegrin and metalloproteinase; ANOVA: Analysis of variance;
RGD domain: Arg-Gly-Asp domain; CCL2 (MCP-1): chemokine (C-C motif)
ligand 2 or monocyte chemoattractant protein-2; CCL5 (RANTES): chemokine
(C-C motif) ligand 5; ELISA: enzyme-linked immunosorbent assay; ERK:
extracellular signal-regulated kinases; [Ca
+2]o: extracellular calcium; CX3CR1:
fractalkine receptor; CX3CL1: fractalkine; GFAP: glial fibrillary acidic protein;
iNOS: inducible nitric oxide synthase; IL-1β: interleukin-1β; [Ca
+2]i: intracellular
calcium; Iba-1: ionized calcium binding adaptor molecule 1; HAND: HIV-
associated neurocognitive disorders; HIV-1: human immunodeficiency virus-
type 1; MAP-2: microtubule-associated protein type-2; MCP-1: monocyte
chemoattractant protein-1; MAPK: mitogen-activated protein kinase; NK cells:
natural killer cells; neuroAIDS: neuro-acquired immunodeficiency syndrome;
NADPH: nicotinamide adenine dinucleotide phosphate oxidase; PI3K:
phosphoinositide 3-kinase; RANTES (CCL5): regulated upon activation, normal
T-cell expressed, and secreted; Tat: transactivator of transcription; TNF-α:
tumor necrosis factor-α; TACE (or ADAM 17): TNF-α converting enzyme.
Acknowledgements
We thank Dr. Dan Littman (Skirball Institute, New York University School of
Medicine, NY, NY) for making available the Cx3cr1
-/- mice. The support of
grants R21 DA028741, P01 DA19398, and K02 DA027374 from the National
Institute on Drug Abuse is gratefully acknowledged.
Author details
1Department of Pharmacology and Toxicology, Virginia Commonwealth
University School of Medicine, Richmond, VA 23298-0613 USA.
2Department
of Anatomy and Neurobiology, Virginia Commonwealth University School of
Medicine, VA 23298-0709 USA.
3Department of Microbiology and
Immunology, Virginia Commonwealth University School of Medicine, VA
23298-0678 USA.
4Institute for Drug and Alcohol Studies, Virginia
Commonwealth University, Richmond, VA 2329-0310 USA.
5Cancer
Pathophysiology Division, National Cancer Center Research Institute (Tsukiji
Campus), 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JAPAN.
Authors’ contributions
MS, JLS, DHC, PEK, and KFH designed the experiments. MS, SZ, NE-H, Y-KH,
and MES conducted the experiments. MS, JLS, DHC, PEK, and KFH analyzed
and interpreted the data and wrote the manuscript. KFH coordinated the
research and supervised the project. All authors have read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 October 2010 Accepted: 17 November 2011
Published: 17 November 2011
References
1. Adler MW, Geller EB, Rogers TJ, Henderson EE, Eisenstein TK: Opioids,
receptors, and immunity. Adv Exp Med Biol 1993, 335:13-20.
2. Kumar R, Orsoni S, Norman L, Verma AS, Tirado G, Giavedoni LD, Staprans S,
Miller GM, Buch SJ, Kumar A: Chronic morphine exposure causes
pronounced virus replication in cerebral compartment and accelerated
onset of AIDS in SIV/SHIV-infected Indian rhesus macaques. Virology
2006, 354:192-206.
3. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr:
Morphine promotes the growth of HIV-1 in human peripheral blood
mononuclear cell cocultures. AIDS 1990, 4:869-873.
4. Donahoe RM, Vlahov D: Opiates as potential cofactors in progression of
HIV-1 infections to AIDS. J Neuroimmunol 1998, 83:77-87.
5. Carr DJJ, Serou M: Exogenous and endogenous opioids as biological
response modifiers. Immunopharmacology 1995, 31:59-71.
6. Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, Persidsky Y,
Volsky DJ, Knapp PE: HIV-1 neuropathogenesis: Glial mechanisms
revealed through substance abuse. J Neurochem 2007, 100:567-586.
7. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, Peng X, Chen KC,
Chauhan A, Haughey N, Cutler R, et al: Increased vulnerability of ApoE4
neurons to HIV proteins and opiates: protection by diosgenin and L-
deprenyl. Neurobiol Dis 2006, 23:109-119.
8. Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, Bruce-Keller AJ,
Knapp PE: Molecular targets of opiate drug abuse in neuroAIDS. Neurotox
Res 2005, 8:63-80.
9. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, Cass W,
Turchan JT: Molecular basis for interactions of HIV and drugs of abuse. J
Acquir Immune Defic Syndr 2002, 31(Suppl 2):S62-S69.
10. Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF:
Synergistic neurotoxicity of opioids and human immunodeficiency virus-
1 Tat protein in striatal neurons in vitro. Neuroscience 2001, 102:555-563.
11. Anthony IC, Arango JC, Stephens B, Simmonds P, Bell JE: The effects of
illicit drugs on the HIV infected brain. Front Biosci 2008, 13:1294-1307.
12. Bell JE, Arango JC, Anthony IC: Neurobiology of multiple insults: HIV-1-
associated brain disorders in those who use illicit drugs. J Neuroimmune
Pharmacol 2006, 1:182-191.
13. Peterson PK, Molitor TW, Chao CC: The opioid-cytokine connection. J
Neuroimmunol 1998, 83:63-69.
14. Chang SL, Wu GD, Patel NA, Vidal EL, Fiala M: The effects of interaction
between morphine and interleukin-1 on the immune response. Adv Exp
Med Biol 1998, 437:67-72.
15. El-Hage N, Bruce-Keller AJ, Knapp PE, Hauser KF: CCL5/RANTES gene
deletion attenuates opioid-induced increases in glial CCL2/MCP-1
immunoreactivity and activation in HIV-1 Tat exposed mice. J
Neuroimmune Pharmacol 2008, 3:275-285.
16. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ,
Hauser KF: HIV-1 Tat and opiate-induced changes in astrocytes promote
chemotaxis of microglia through the expression of MCP-1 and
alternative chemokines. Glia 2006, 53:132-146.
17. El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF: Synergistic
increases in intracellular Ca
2+, and the release of MCP-1, RANTES, and
IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 2005,
50:91-106.
18. Rogers TJ, Peterson PK: Opioid G protein-coupled receptors: signals at the
crossroads of inflammation. Trends Immunol 2003, 24:116-121.
19. Szabo I, Wetzel MA, Zhang N, Steele AD, Kaminsky DE, Chen C, Liu-Chen LY,
Bednar F, Henderson EE, Howard OM, et al: Selective inactivation of CCR5
and decreased infectivity of R5 HIV-1 strains mediated by opioid-
induced heterologous desensitization. J Leukoc Biol 2003, 74:1074-1082.
20. Parenty G, Appelbe S, Milligan G: CXCR2 chemokine receptor antagonism
enhances DOP opioid receptor function via allosteric regulation of the
CXCR2-DOP receptor heterodimer. Biochem J 2008, 412:245-256.
21. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM,
Toro MJ, Lucas P, Monterrubio M, Martinez A, Mellado M: Ligand
stabilization of CXCR4/delta-opioid receptor heterodimers reveals a
mechanism for immune response regulation. Eur J Immunol 2008,
38:537-549.
22. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY: Heterodimerization
and cross-desensitization between the mu-opioid receptor and the
chemokine CCR5 receptor. Eur J Pharmacol 2004, 483:175-186.
Suzuki et al. Molecular Neurodegeneration 2011, 6:78
http://www.molecularneurodegeneration.com/content/6/1/78
Page 15 of 1723. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR,
Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a
CX3C motif. Nature 1997, 385:640-644.
24. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M,
Takagi S, Nomiyama H, Schall TJ, et al: Identification and molecular
characterization of fractalkine receptor CX3CR1, which mediates both
leukocyte migration and adhesion. Cell 1997, 91:521-530.
25. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH: Expression of
fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic
inflammation in the rodent CNS. Glia 2002, 37:314-327.
26. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A,
Littman DR: Analysis of fractalkine receptor CX(3)CR1 function by
targeted deletion and green fluorescent protein reporter gene insertion.
Mol Cell Biol 2000, 20:4106-4114.
27. Rossi DL, Hardiman G, Copeland NG, Gilbert DJ, Jenkins N, Zlotnik A,
Bazan JF: Cloning and characterization of a new type of mouse
chemokine. Genomics 1998, 47:163-170.
28. Savarin-Vuaillat C, Ransohoff RM: Chemokines and chemokine receptors in
neurological disease: raise, retain, or reduce? Neurotherapeutics 2007,
4:590-601.
29. Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K, Irani K,
Becker LC: Fractalkine upregulates intercellular adhesion molecule-1 in
endothelial cells through CX3CR1 and the Jak Stat5 pathway. Circ Res
2007, 101:1001-1008.
30. Re DB, Przedborski S: Fractalkine: moving from chemotaxis to
neuroprotection. Nat Neurosci 2006, 9:859-861.
31. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM:
Identification of CX3CR1. A chemotactic receptor for the human CX3C
chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem
1998, 273:23799-23804.
32. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B,
Delfraissy JF, McDermott DH, Murphy PM, Debre P, et al: Rapid progression
to AIDS in HIV+ individuals with a structural variant of the chemokine
receptor CX3CR1. Science 2000, 287:2274-2277.
33. Shimizu N, Tanaka A, Oue A, Mori T, Ohtsuki T, Apichartpiyakul C,
Uchiumi H, Nojima Y, Hoshino H: Broad usage spectrum of G protein-
coupled receptors as coreceptors by primary isolates of HIV. AIDS 2009,
27:761-769.
34. Becker Y: The spreading of HIV-1 infection in the human organism is
caused by fractalkine trafficking of the infected lymphocytes–a review,
hypothesis and implications for treatment. Virus Genes 2007, 34:93-109.
35. Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N,
Kume T, Akaike A, Satoh M: Localization of fractalkine and CX3CR1
mRNAs in rat brain: does fractalkine play a role in signaling from neuron
to microglia? FEBS Lett 1998, 429:167-172.
36. Meucci O, Fatatis A, Simen AA, Miller RJ: Expression of CX3CR1 chemokine
receptors on neurons and their role in neuronal survival. Proc Natl Acad
Sci (USA) 2000, 97:8075-8080.
37. Ransohoff RM, Liu L, Cardona AE: Chemokines and chemokine receptors:
multipurpose players in neuroinflammation. Int Rev Neurobiol 2007,
82:187-204.
38. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM,
Huang D, Kidd G, Dombrowski S, Dutta R, et al: Control of microglial
neurotoxicity by the fractalkine receptor. Nat Neurosci 2006, 9:917-924.
39. Tong N, Perry SW, Zhang Q, James HJ, Guo H, Brooks A, Bal H, Kinnear SA,
Fine S, Epstein LG, et al: Neuronal fractalkine expression in HIV-1
encephalitis: roles for macrophage recruitment and neuroprotection in
the central nervous system. J Immunol 2000, 164:1333-1339.
40. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G,
Haass C, LaFerla FM, Kretzschmar H, Herms J: Microglial Cx3cr1 knockout
prevents neuron loss in a mouse model of Alzheimer’s disease. Nat
Neurosci 2010, 13:411-413.
41. Erichsen D, Lopez AL, Peng H, Niemann D, Williams C, Bauer M, Morgello S,
Cotter RL, Ryan LA, Ghorpade A, et al: Neuronal injury regulates
fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol
2003, 138:144-155.
42. Cotter R, Williams C, Ryan L, Erichsen D, Lopez A, Peng H, Zheng J:
Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-
associated dementia. J Neurovirol 2002, 8:585-598.
43. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, Marquie-
Beck J, Navia B, HIV Neuroimaging Consortium: Chemokines in
cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-
infected individuals. J Neurovirol 2011, 17:63-69.
44. Depboylu C, Eiden LE, Schafer MK, Reinhart TA, Mitsuya H, Schall TJ,
Weihe E: Fractalkine expression in the rhesus monkey brain during
lentivirus infection and its control by 6-chloro-2’,3’-dideoxyguanosine. J
Neuropathol Exp Neurol 2006, 65:1170-1180.
45. Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasselin I, Coulomb-
L’Hermine A, Krzysiek R, Galanaud P, Levy Y, Emilie D: Deregulation of the
expression of the fractalkine/fractalkine receptor complex in HIV-1-
infected patients. Blood 2001, 98:1678-1686.
46. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ: Chemokines
regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc
Natl Acad Sci (USA) 1998, 95:14500-14505.
47. Lauro C, Catalano M, Trettel F, Mainiero F, Ciotti MT, Eusebi F, Limatola C:
The chemokine CX3CL1 reduces migration and increases adhesion of
neurons with mechanisms dependent on the beta1 integrin subunit. J
Immunol 2006, 177:7599-7606.
48. Brake DA, Debouck C, Biesecker G: Identification of an Arg-Gly-Asp (RGD)
cell adhesion site in human immunodeficiency virus type 1
transactivation protein, tat. J Cell Biol 1990, 111:1275-1281.
49. Barillari G, Gendelman R, Gallo RC, Ensoli B: The Tat protein of HIV, a
growth factor for AIDS Kaposi sarcoma and cytokine activated vascular
cells, induces adhesion of the same cell types by using integrin
receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci
(USA) 1993, 90:7941-7945.
50. Toschi E, Bacigalupo I, Strippoli R, Cereseto A, Falchi M, Chiozzini C, Nappi F,
Sgadari C, Barillari G, Mainiero F, et al: HIV-1 Tat Regulates Endothelial Cell
Cycle Progression via Activation of the Ras/ERK MAPK Signaling
Pathway. Mol Biol Cell 2006, 17:1985-1994.
51. Vogel BE, Lee S, Hildebrand A, Craig W, Pierschbacher MD, Wong-Stall F,
Ruoslahti E: A novel integrin specificity exemplified by binding of the
αvβ 5 integrin to the basic domain of the HIV Tat protein and
vitronectin. J Cell Biol 1993, 121:461-468.
52. Chen X, Geller EB, Rogers TJ, Adler MW: The chemokine CX3CL1/
fractalkine interferes with the antinociceptive effect induced by opioid
agonists in the periaqueductal grey of rats. Brain Res 2007, 1153:52-57.
53. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J,
Langer S, Martin D, Green P, Fleshner M, et al: A role for proinflammatory
cytokines and fractalkine in analgesia, tolerance, and subsequent pain
facilitation induced by chronic intrathecal morphine. J Neurosci 2004,
24:7353-7365.
54. Sheng WS, Hu S, Ni HT, Rock RB, Peterson PK: WIN55,212-2 Inhibits
Production of CX3CL1 by Human Astrocytes: Involvement of p38 MAP
Kinase. J Neuroimmune Pharmacol 2009, 4:244-248.
55. Thomas DM, Francescutti-Verbeem DM, Kuhn DM: Methamphetamine-
induced neurotoxicity and microglial activation are not mediated by
fractalkine receptor signaling. J Neurochem 2008, 106:696-705.
56. Lindia JA, McGowan E, Jochnowitz N, Abbadie C: Induction of CX3CL1
expression in astrocytes and CX3CR1 in microglia in the spinal cord of a
rat model of neuropathic pain. J Pain 2005, 6:434-438.
57. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ,
Raines EW: Tumor necrosis factor-alpha-converting enzyme (ADAM17)
mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem
2001, 276:37993-38001.
58. Croitoru-Lamoury J, Guillemin GJ, Dormont D, Brew BJ: Quinolinic acid up-
regulates chemokine production and chemokine receptor expression in
astrocytes. Adv Exp Med Biol 2003, 527:37-45.
59. Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O:
Interactions between chemokines: regulation of fractalkine/CX3CL1
homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 2010,
285:10563-10571.
60. Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE:
Morphine potentiates neurodegenerative effects of HIV-1 Tat through
actions at μ-opioid receptor-expressing glia. Brain 2011.
61. Singh IN, El-Hage N, Campbell ME, Lutz SE, Knapp PE, Nath A, Hauser KF:
Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and
gp120-induced apoptosis and neurite degeneration in striatal neurons.
Neuroscience 2005, 135:781-790.
62. Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, Knapp PE, Nath A,
Hauser KF: Apoptotic death of striatal neurons induced by HIV-1 Tat and
Suzuki et al. Molecular Neurodegeneration 2011, 6:78
http://www.molecularneurodegeneration.com/content/6/1/78
Page 16 of 17gp120: differential involvement of caspase-3 and endonuclease G. J
Neurovirol 2004, 10:141-151.
63. Zou S, El-Hage N, Podhaizer EM, Knapp PE, Hauser KF: PTEN gene silencing
prevents HIV-1 gp120IIIB-induced degeneration of striatal neurons. J
Neurovirol 2011, 17:41-49.
64. Bakalkin G, Watanabe H, Jezierska J, Depoorter C, Verschuuren-
Bemelmans C, Bazov I, Artemenko KA, Yakovleva T, Dooijes D, et al:
Prodynorphin mutations cause the neurodegenerative disorder
spinocerebellar ataxia type 23. Am J Hum Genet 2010, 87:593-603.
65. Friedl P: Prespecification and plasticity: shifting mechanisms of cell
migration. Curr Opin Cell Biol 2004, 16:14-23.
66. Inoue K: Purinergic systems in microglia. Cell Mol Life Sci 2008,
65:3074-3080.
67. Horvath RJ, Deleo JA: Morphine enhances microglial migration through
modulation of P2X4 receptor signaling. J Neurosci 2009, 29:998-1005.
68. Luo Y, Berman MA, Abromson-Leeman SR, Dorf ME: Tumor necrosis factor
is required for RANTES-induced astrocyte monocyte chemoattractant
protein-1 production. Glia 2003, 43:119-127.
69. Benveniste EN, Benos DJ: TNF-alpha- and IFN-gamma-mediated signal
transduction pathways: effects on glial cell gene expression and
function. FASEB J 1995, 9:1577-1584.
70. El-Hage N, Bruce-Keller AJ, Yakovleva T, Bakalkin G, Knapp PE, Hauser KF:
Morphine exacerbates HIV-1 Tat-induced cytokine production in
astrocytes through convergent effects on [Ca
2+]i, NF-κB trafficking and
transcription. PLoS ONE 2008, 3:e4093.
71. Heinisch S, Palma J, Kirby LG: Interactions between chemokine and mu-
opioid receptors: anatomical findings and electrophysiological studies in
the rat periaqueductal grey. Brain Behav Immun 2011, 25:360-372.
72. Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T, Yun-Ke Y, Wen-
Wei L, Xiang-Yu W, Jun M, et al: New evidences for fractalkine/CX3CL1
involved in substantia nigral microglial activation and behavioral
changes in a rat model of Parkinson’s disease. Neurobiol Aging 2011,
32:443-458.
73. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P,
Giustetto M, Ferreira TA, Guiducci E, Dumas L, et al: Synaptic pruning by
microglia is necessary for normal brain development. Science 2011,
333:1456-1458.
74. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K,
Hartmann D, Fahrenholz F, Postina R, Matthews V, et al: The disintegrin-like
metalloproteinase ADAM10 is involved in constitutive cleavage of
CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.
Blood 2003, 102:1186-1195.
75. Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S,
Broadway N, Hartmann D, Saftig P, Umland S, et al: ADAM10 is a principal
‘sheddase’ of the low-affinity immunoglobulin E receptor CD23. Nat
Immunol 2006, 7:1293-1298.
76. Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von HP,
Winter U, Paliga K, Reiss K, Saftig P, et al: Regulated shedding of
transmembrane chemokines by the disintegrin and metalloproteinase
10 facilitates detachment of adherent leukocytes. J Immunol 2007,
178:8064-8072.
77. Tsubota K, Nishiyama T, Mishima K, Inoue H, Doi T, Hattori Y, Kodama T,
Higuchi A, Hayashi Y, Saito I: The role of fractalkine as an accelerating
factor on the autoimmune exocrinopathy in mice. Invest Ophthalmol Vis
Sci 2009, 50:4753-4760.
78. Wildenberg ME, van Helden-Meeuwsen CG, Drexhage HA, Versnel MA:
Altered fractalkine cleavage potentially promotes local inflammation in
NOD salivary gland. Arthritis Res Ther 2008, 10:R69.
79. Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K, Irani K,
Becker LC: Fractalkine upregulates intercellular adhesion molecule-1 in
endothelial cells through CX3CR1 and the Jak Stat5 pathway. Circ Res
2007, 101:1001-1008.
80. Garin A, Tarantino N, Faure S, Daoudi M, Lecureuil C, Bourdais A, Debre P,
Deterre P, Combadiere C: Two novel fully functional isoforms of CX3CR1
are potent HIV coreceptors. J Immunol 2003, 171:5305-5312.
81. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering
the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
82. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F: CB2 receptors
in the brain: role in central immune function. Br J Pharmacol 2008,
153:240-251.
83. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune
privilege: hiding in plain sight. Immunol Rev 2006, 213:48-65.
84. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat
Rev Immunol 2005, 5:69-81.
85. Gupta S, Knight AG, Gupta S, Knapp PE, Hauser KF, Keller JN, Bruce-
Keller AJ: HIV-Tat elicits microglial glutamate release: role of NAPDH
oxidase and the cystine-glutamate antiporter. Neurosci Lett 2010,
485:233-236.
86. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW:
CCL2/monocyte chemoattractant protein-1 mediates enhanced
transmigration of human immunodeficiency virus (HIV)-infected
leukocytes across the blood-brain barrier: a potential mechanism of HIV-
CNS invasion and NeuroAIDS. J Neurosci 2006, 26:1098-1106.
87. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM,
Lamb BT: Regulation of tau pathology by the microglial fractalkine
receptor. Neuron 2010, 68:19-31.
88. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR: Role of the
CX3CR1/p38 MAPK pathway in spinal microglia for the development of
neuropathic pain following nerve injury-induced cleavage of fractalkine.
Brain Behav Immun 2007, 21:642-651.
89. Hulshof S, van Haastert ES, Kuipers HF, van den Elsen PJ, De Groot CJ,
vand V, Ravid R, Biber K: CX3CL1 and CX3CR1 expression in human brain
tissue: noninflammatory control versus multiple sclerosis. J Neuropathol
Exp Neurol 2003, 62:899-907.
90. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui X, Matsumiya T,
Tanji K, Shibata T, Tamo W, et al: Synergistic stimulation, by tumor
necrosis factor-alpha and interferon-gamma, of fractalkine expression in
human astrocytes. Neurosci Lett 2001, 303:132-136.
91. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ: Role of CX3CR1
(fractalkine receptor) in brain damage and inflammation induced by
focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008,
28:1707-1721.
92. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C,
Gallo RC, Major EO: Induction of monocyte chemoattractant protein-1 in
HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc
Natl Acad Sci (USA) 1998, 95:3117-3121.
93. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Guerin T, Chauhan A, Reid R,
Xu R, Nath A, Knapp PE, Hauser KF: Morphine causes rapid increases in
glial activation and neuronal injury in the striatum of inducible HIV-1 Tat
transgenic mice. Glia 2008, 56:1414-1427.
94. Sholl DA: Dendritic organization in the neurons of the visual and motor
cortices of the cat. J Anat (London) 1953, 87:387-407.
95. Hauser KF, McLaughlin PJ, Zagon IS: Endogenous opioid systems and the
regulation of dendritic growth and spine formation. J Comp Neurol 1989,
281:13-22.
doi:10.1186/1750-1326-6-78
Cite this article as: Suzuki et al.: Fractalkine/CX3CL1 protects striatal
neurons from synergistic morphine and HIV-1 Tat-induced dendritic
losses and death. Molecular Neurodegeneration 2011 6:78.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Suzuki et al. Molecular Neurodegeneration 2011, 6:78
http://www.molecularneurodegeneration.com/content/6/1/78
Page 17 of 17